Today
before the opening bell, Zenosense reported on the status of development
operations for its MRSA and lung cancer detection devices. Development efforts
have been moving forward as planned. In its news release, Zenosense disclosed
the following summarized recent achievements:
MRSA/SA
• A new sensor has been defined for
manufacturing. It includes a new MRSA/SA VOC (Volatile Organic Compound)
biomarker micro-separator technology.
• For this new technology, tests have
been initiated to measure and contrast cultures of MRSA and SA.
• Electronics design for a microbiology
lab device is complete, and industrial design for the device is in process.
• The electronics and new sensor are
expected to be integrated in the coming weeks to produce the first prototype
for laboratory detection of MRSA/SA in cultures.
Lung
Cancer
• First tests using a LC VOC biomarker
selected from existing hospital research data have been carried out.
• Good sensitivity to this VOC
biomarker using the current sensor has been obtained, the VOC biomarker
typically being expressed by LC patients at levels well within the capability
of the sensor.
• Further tests will be carried out
with the intent to resolve issues with cross-sensitivity with other VOC
biomarkers and other ambient compounds.
• A review of literature and current
research is in hand with alternative VOC biomarkers identified.
• A device for clinical tests with lung
cancer patients has been designed, including electronics and a VOC capturing
system. It is intended for this device to meet hospital clinical procedure
requirements.
With
its respected partner Sgenia Group, Zenosense seeks to develop effective
medical devices targeting the early detection of both deadly bacteria and
certain cancers in the exhaled breath of patients. It intends to market and
sell these products to hospitals and primary healthcare facilities. Intended
for the timely detection of Methicillin-resistant Staphylococcus aureus
“Super-Bug” (MRSA) and lung cancer, these devices incorporate an advanced
electronic nose technology to identify VOC signatures given by patients with
this infection/illness.
For
more information, visit: www.zenosense.net
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign
up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please
see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment